Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses

Fig. 1

Flow chart showing the participants undergoing microbiome analysis. Overall, 99 patients with RA (who had been treated for at least a year) and 30 healthy participants were enrolled in the study. A tofacitinib user and 4 patients with malignancy were excluded from the final analysis. Patients with RA were divided according to the use of biological DMARDs, as well as disease activity (remission: DAS28 < 2.6, low disease activity: 2.6 ≤ DAS28 ≤ 3.2, moderate disease activity: 3.2 < DAS28 ≤ 5.1, high disease activity: DAS28 > 5.1), at the time of stool collection. In patients with moderate-to-high disease activity, therapeutic changes were recorded, and the response after 6 months was followed-up. bDMARDs, biological disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic DMARDs; F/U, follow-up

Back to article page